Integrating New PAH Therapies into Clinical Practice

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

Now Viewing

EP: 8.Integrating New PAH Therapies into Clinical Practice

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

• Sotatercept, a new treatment for PAH, recently received FDA approval in April 2024. How do you see this new therapy, as well as other emerging pulmonary arterial hypertension (PAH) treatments, fitting into the current treatment paradigm for PAH?
• What key factors should guide clinicians in determining the appropriate use of these new therapies in clinical practice?